Implementing MyChoice® CDx HRD testing for the Nordics: lessons from 2021 to 2023
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Implementing MyChoice® CDx HRD testing for the Nordics : lessons from 2021 to 2023. / Korsholm, Lea Milling; Broecker, Verena; Mirza, Mansoor Raza; Rossing, Maria.
In: Acta Oncologica, Vol. 63, 2024, p. 70-75.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Implementing MyChoice® CDx HRD testing for the Nordics
T2 - lessons from 2021 to 2023
AU - Korsholm, Lea Milling
AU - Broecker, Verena
AU - Mirza, Mansoor Raza
AU - Rossing, Maria
N1 - Publisher Copyright: © 2024 The Author(s). Published by MJS Publishing on behalf of Acta Oncologica.
PY - 2024
Y1 - 2024
N2 - Background: Assessment of homologous recombinant deficient (HRD) phenotypes is key for managing Poly (ADP-ribose) polymerase inhibitor (PARPi) treatment. To accommodate the need for a validated HRD platform and enhance targeted treatment of ovarian cancer patients, a Nordic core facility for the myChoice® CDx platform was established in Denmark. Materials and methods: Comparative calculations and statistics are based on information from test requisitions and results (Genome Instability Score [GIS], BRCA status and combined HRD status) obtained from ovarian and breast cancer samples submitted for HRD-testing by myChoice® CDx through the Nordic core facility in the 2-year period. Results: Copenhagen University Hospital received 1,948 requisitions during the 2-year period. Conclusive results were obtained in 89% of the tests, while 7% were inconclusive due to the lack of GIS and 4% were not able to be analysed. Comparing the conclusive HRD status results across countries, Sweden had the highest percentage of HRD positives (38%) compared to Denmark, Norway, and Finland (28–32%). Interpretation: The myChoice® CDx Nordic core facility has been well received among the Nordic countries and provides new insights on the influence of national guidelines on HRD testing. Overall, we experienced an efficient turnaround time and a high fraction of conclusive results. Interestingly, prior somatic BRCA testing is redundant when assessing HRD status through myChoice® CDx test since somatic BRCA screening is already a significant component of the myChoice® CDx test. Thus, it should be considered to omit prior somatic BRCA testing to ensure a rationalised HRD diagnostic flow optimised for clinical use.
AB - Background: Assessment of homologous recombinant deficient (HRD) phenotypes is key for managing Poly (ADP-ribose) polymerase inhibitor (PARPi) treatment. To accommodate the need for a validated HRD platform and enhance targeted treatment of ovarian cancer patients, a Nordic core facility for the myChoice® CDx platform was established in Denmark. Materials and methods: Comparative calculations and statistics are based on information from test requisitions and results (Genome Instability Score [GIS], BRCA status and combined HRD status) obtained from ovarian and breast cancer samples submitted for HRD-testing by myChoice® CDx through the Nordic core facility in the 2-year period. Results: Copenhagen University Hospital received 1,948 requisitions during the 2-year period. Conclusive results were obtained in 89% of the tests, while 7% were inconclusive due to the lack of GIS and 4% were not able to be analysed. Comparing the conclusive HRD status results across countries, Sweden had the highest percentage of HRD positives (38%) compared to Denmark, Norway, and Finland (28–32%). Interpretation: The myChoice® CDx Nordic core facility has been well received among the Nordic countries and provides new insights on the influence of national guidelines on HRD testing. Overall, we experienced an efficient turnaround time and a high fraction of conclusive results. Interestingly, prior somatic BRCA testing is redundant when assessing HRD status through myChoice® CDx test since somatic BRCA screening is already a significant component of the myChoice® CDx test. Thus, it should be considered to omit prior somatic BRCA testing to ensure a rationalised HRD diagnostic flow optimised for clinical use.
KW - biomarker
KW - BRCA
KW - cancer
KW - HRD
KW - Myriad
KW - Ovarian
KW - PARPi
U2 - 10.2340/1651-226X.2024.34139
DO - 10.2340/1651-226X.2024.34139
M3 - Journal article
C2 - 38482597
AN - SCOPUS:85187733340
VL - 63
SP - 70
EP - 75
JO - Acta Oncologica
JF - Acta Oncologica
SN - 1100-1704
ER -
ID: 386412625